Carina Medical

What Carina Medical does

Carina Medical LLC, doing business as Carina AI, develops on-premise AI-native software for clinical research and radiation oncology at academic medical centers. Founded in 2018 as a spin-out from research labs at the University of Virginia and University of Kentucky by biomedical engineer Xue Feng, PhD, and medical physicist Quan Chen, PhD, the company is headquartered in Lexington, KY and operates as a privately held LLC with 1-10 employees. Its portfolio spans the full clinical AI arc from raw data to FDA-cleared product on a single on-premise stack.

The core technology platform is CuratAI, an on-premise multimodal data curation system that retrieves imaging and clinical data from PACS, EHR, and pathology systems; converts unstructured text to structured fields via a local 7B-parameter LLM; performs pixel-level de-identification across five PHI vectors; supports AI-assisted 3D annotation; and enables cross-institution sharing with PHI safeguards. Built on the same architecture are two FDA 510(k)-cleared products: INTContour (K212274), an AI auto-contouring platform covering 120+ OARs across CT, MRI, and PET/CT with incremental retraining on institutional protocols; and INTDose (K213137), a TPS-independent Monte Carlo 3D dose verification engine that completes a plan in under five minutes. Research-grade products include the OncoAI Suite (six cancer detection/segmentation engines) and QuantBrain (ventricle volumetrics for hydrocephalus). The company holds 5+ granted US patents and 40+ peer-reviewed publications, with validation studies co-developed at Mayo Clinic, Penn, and the STAR neurovascular registry.

Carina AI sells through enterprise field sales to academic medical centers, with demo requests and 30-minute clinical walkthroughs as the primary engagement model and an event-driven presence at RSNA, ASTRO, SIIM, and CNS. Revenue comes from enterprise software licensing (subscription/recurring) for CuratAI, INTContour, INTDose, OncoAI, and QuantBrain, supplemented by professional services for data aggregation, custom AI development, annotation, and 510(k) pathway support. Pricing is not publicly disclosed and is governed by separate software license agreements. The company has been funded primarily through 5+ NIH SBIR Phase I/Phase II awards totaling over $3M, with no disclosed institutional equity rounds.

Name

Carina Medical

Legal name

Carina Medical LLC

Website

https://carinaai.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Carina Medical develops on-premise AI-native software for clinical research and radiation oncology at academic medical centers, with FDA-cleared auto-contouring and dose verification tools plus the CuratAI data curation platform.

Ownership category

akta.pro rank

Product category

Radiation Oncology AI Software

NAICS

Software Publishers (5132)

SIC

Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industries

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ), Oncology Telemedicine Platforms (HLALAGAH)

Keywords

• Radiation oncology software
• Medical imaging AI
• Clinical data curation
• Auto-contouring software
• Dose verification software

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Software Licenses: Enterprise software licensing for on-premise clinical research and FDA-cleared clinical AI products. Software governed by separate Software License Agreements. Products include CuratAI, INTContour, INTDose, OncoAI, QuantBrain.
2. Professional Services: Partner services including data aggregation & de-identification setup, annotation & cohort building, custom AI development, and regulatory/510(k) pathway support. Staffed by the same engineers who built the platform.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

Carina Medical develops on-premise AI-native clinical research and radiation oncology software. Its flagship CuratAI platform curates multimodal clinical data (PACS, EHR, pathology) with privacy-preserving de-identification, while its FDA 510(k)-cleared INTContour and INTDose products deliver AI auto-contouring and Monte Carlo dose verification for cancer treatment planning.

Product overview

Carina AI offers a unified on-premise clinical AI platform centered on data curation (CuratAI), FDA-cleared radiation oncology tools (INTContour, INTDose), and research-grade oncology AI (OncoAI Suite, QuantBrain). The portfolio spans from raw clinical data retrieval through de-identification, annotation, AI model training, and FDA clearance — all executed on-premise with no PHI leaving the institutional firewall. Open-source DICOM tools complement the commercial stack.

Differentiator

Problem solved

Functional benefit

Brands

• CuratAI: AI-Native Multimodal Data Curation Platform — on-premise clinical-research data platform for retrieval, ingest, de-identification, annotation, and cross-institution sharing.
• INTContour
• OncoAI Suite
• QuantBrain
• INTDose
• Open-Source DICOM Tools

Products and services

• CuratAI On-premise multimodal clinical-research data curation platform covering six stages: PACS/EHR/pathology retrieval, unstructured-to-structured ingestion via local LLM, pixel-level de-identification across five PHI vectors, AI-assisted 3D annotation, custom AI plugin deployment, and cross-institution sharing with PHI safeguards. Built for research informatics teams at academic medical centers.
• INTContour FDA 510(k)-cleared AI auto-contouring platform for radiation oncology providing 120+ organ-at-risk segmentations across CT, MRI, and PET/CT for head & neck, thorax, abdomen, and pelvis, with built-in QA metrics and incremental retraining capability for custom institutional protocols.
• INTDose FDA 510(k)-cleared Monte Carlo 3D secondary dose verification platform for radiation therapy QA. TPS-neutral independent recalculation with gamma index analysis and per-structure DVH comparison, processing plans in under 5 minutes; compatible with Varian Eclipse, Philips Pinnacle, Varian Halcyon, and Tomotherapy.
• OncoAI Suite Multi-modality oncology imaging suite with six AI engines: BrainTumor, LymphNode, LungNodule, KidneyTumor, LiverTumor, and PET/CT whole-body lesion segmentation — covering CT, MRI, and PET/CT. Three-stage pipeline using RetinaUNet3D for detection, EfficientNetV2S for triage, and UNet3D for segmentation.
• QuantBrain AI-native brain quantification platform for automatic ventricle segmentation and volumetric measurement on CT and MRI (T1, T1c, T2, FLAIR), computing Evans Index from 3D masks with per-scan uncertainty scores and longitudinal comparison across serial timepoints. Validated across four disease populations.
• Open-Source DICOM Tools Collection of free web-based DICOM utilities including DICOM Anonymizer, DICOM Contour Comparator (Dice/Hausdorff/mean surface distance), NRG Analyzer (deformable registration QA), and TG-306 Dynamic Jaw QA tool.

Quantifiable outcome

• CuratAI defacing completes successfully on 100% of brain CT scans and 96.9% of head-and-neck CT/PET/dose scans
• +5 more outcomes

Named customers11 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability7 records

Feature7 records

Partnerships

Three partnerships are on record, tiered core.

• University of PennsylvaniacoreStrategic or Co-development Partner · 1 January 2026Penn radiation oncology team benchmarked four defacing algorithms including CuratAI's across 185 patients. CuratAI delivered best privacy-utility trade-off. Study published in International Journal of Radiation Oncology Biology Physics (Red Journal), 2026.
• STAR Registry (Stroke Thrombectomy and Aneurysm Registry)coreStrategic or Co-development Partner · 1 January 2026STAR Registry (founded at MUSC, 85+ sites, 15,000+ patients) partnered to validate CuratAI's local LLM extraction. 87.7% accuracy on 170 evaluable fields against REDCap ground truth. Paper submitted to Neurosurgery, 2026.
• Mayo Clinic ArizonacoreStrategic or Co-development Partner · 1 January 2023Mayo Clinic Arizona radiation oncology retrained INTContour on 100 local prostate cases with iodinated spacers and rectal balloons. Blinded review by 6 GU radiation oncologists found AI contours rated ≥ manual in ≥50% across all structures. Study published in Medical Physics, 2023 and Radiotherapy & Oncology, 2025.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Flywheel: Flywheel is a clinical research data platform for imaging and biomedical data curation, federated analysis, and AI training. Comparable to CuratAI's data curation and multi-site study enablement layer, with broader life sciences and pharma exposure.
• Segmed: Segmed provides a clinical imaging data curation and licensing platform aggregating de-identified medical images for AI training. Adjacent to CuratAI in the on-prem/secure clinical data curation niche serving AI research teams.

Broad incumbents

• Elekta: Elekta is a global radiation oncology and radiosurgery hardware/software incumbent (Monaco TPS, linacs). Broad incumbent comparable through embedded AI roadmap in its TPS and oncology informatics products.
• Varian Medical Systems (Siemens Healthineers): Varian is the dominant radiation oncology TPS vendor (Eclipse) and linac manufacturer, with growing embedded AI capabilities including auto-contouring. As a broad incumbent, Varian competes indirectly by bundling AI into its installed base that INTDose and INTContour overlay onto.
• RaySearch Laboratories: RaySearch Laboratories is an established incumbent in radiation oncology treatment planning (RayStation) and is increasingly embedding AI auto-contouring and dose optimization. Broader TPS + AI platform versus Carina's focused AI overlay products.

Direct peers

• Radformation: Radformation sells AI-driven automation software for radiation oncology treatment planning, including auto-contouring, plan checking, and QA. Direct overlap with Carina's radiation oncology AI suite, targeting the same medical physicist and dosimetrist buyer at cancer centers.
• Limbus AI: Limbus AI (formerly Limbus Contour) offers FDA-cleared, cloud-distributed AI auto-contouring for radiation oncology with similar OAR coverage to INTContour. Direct competitor in AI auto-contouring for CT/MRI-based radiation therapy planning.
• MVision AI: MVision AI provides AI-based auto-contouring and treatment planning automation for radiation oncology. Comparable as a focused clinical AI vendor serving European and US cancer centers with FDA-cleared contouring products.
• Mirada Medical: Mirada Medical develops AI-driven medical imaging software for oncology, including auto-contouring and multi-modality segmentation. Comparable as a clinical AI imaging vendor with overlap in radiation oncology and oncology imaging workflows.
• MIM Software: MIM Software provides medical imaging analysis and AI workflow tools for radiation oncology, including auto-contouring and dose verification products. Directly comparable to Carina's INTContour and INTDose as a clinical AI vendor serving radiation oncology departments at AMCs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/carina-ai

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Carina Medical